NasdaqCM - Delayed Quote • USD
Acurx Pharmaceuticals, Inc. (ACXP)
At close: June 7 at 4:00 PM EDT
After hours: June 7 at 7:58 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 2 | 2 | 2 | 2 |
| Avg. Estimate | -0.22 | -0.21 | -1.03 | -1.59 |
| Low Estimate | -0.28 | -0.26 | -1.28 | -2.32 |
| High Estimate | -0.16 | -0.17 | -0.78 | -0.86 |
| Year Ago EPS | -0.28 | -0.24 | -1.15 | -1.03 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 1 | 1 | 2 | 2 |
| Avg. Estimate | -- | -- | -- | -- |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | -- | -- | -- | -- |
| Year Ago Sales | -- | -- | -- | -- |
| Sales Growth (year/est) | -- | -- | -- | -- |
Earnings History
| CURRENCY IN USD | 6/30/2023 | 9/30/2023 | 12/31/2023 | 3/31/2024 |
|---|---|---|---|---|
| EPS Est. | -0.27 | -0.27 | -0.26 | -0.24 |
| EPS Actual | -0.28 | -0.24 | -0.37 | -0.28 |
| Difference | -0.01 | 0.03 | -0.11 | -0.04 |
| Surprise % | -3.70% | 11.10% | -42.30% | -16.70% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.22 | -0.21 | -1.03 | -1.59 |
| 7 Days Ago | -0.22 | -0.21 | -1.03 | -1.59 |
| 30 Days Ago | -0.2 | -0.18 | -0.97 | -2.3 |
| 60 Days Ago | -0.2 | -0.18 | -0.97 | -2.3 |
| 90 Days Ago | -0.2 | -0.2 | -0.83 | -1.48 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | ACXP | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 21.40% | -- | -- | 9.10% |
| Next Qtr. | 12.50% | -- | -- | 11.50% |
| Current Year | 10.40% | -- | -- | 5.70% |
| Next Year | -54.40% | -- | -- | 12.60% |
| Next 5 Years (per annum) | -- | -- | -- | 11.34% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Reiterates | HC Wainwright & Co.: Buy to Buy | 5/16/2024 |
| Maintains | HC Wainwright & Co.: Buy to Buy | 3/19/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 2/28/2024 |
| Maintains | HC Wainwright & Co.: Buy to Buy | 12/15/2023 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 11/15/2023 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 9/13/2023 |
Related Tickers
NGENF NervGen Pharma Corp.
1.4600
+8.15%
EDSA Edesa Biotech, Inc.
4.5899
-0.44%
MDNAF Medicenna Therapeutics Corp.
1.7500
+1.16%
NGEN.V NervGen Pharma Corp.
2.0000
+7.53%
CAPR Capricor Therapeutics, Inc.
5.24
-4.38%
COYA Coya Therapeutics, Inc.
7.19
+3.01%
BCTX BriaCell Therapeutics Corp.
1.3900
-2.80%
VCNX Vaccinex, Inc.
7.43
+4.94%
BETRF BetterLife Pharma Inc.
0.0870
+1.16%
DRMA Dermata Therapeutics, Inc.
3.3000
-5.44%